Blood Podcast How I Treat Myeloproliferative Neoplasms
Apr 17, 2025
Join experts Andreas Reiter, a professor specializing in myeloid lympho-neoplasms, Claire Harrison, who co-authored key research on treating low-risk polycythemia vera, and Aaron Gerds, a doctor focusing on anemia in myelofibrosis. They discuss groundbreaking advances in treating myeloproliferative neoplasms, highlighting the importance of personalized medicine. Learn about evolving strategies for managing polycythemia vera, the complexities of anemia treatment, and the significance of thorough testing for rare conditions. Their insights pave the way for enhanced patient care.
AI Snips
Chapters
Transcript
Episode notes
Rethinking Low-Risk PV Management
- Low-risk polycythemia vera (PV) patients still have significantly higher lifetime risk of thrombosis than age-matched general population.
- Multiple factors beyond age and thrombosis history, like leukocytosis and spleen size, must be considered in cytoreduction decisions.
Complex Causes of MF Anemia
- Anemia in myelofibrosis is multifactorial, involving marrow failure, inflammation, treatment effects, and sequestration mechanisms.
- Understanding individual anemia drivers is key to personalized treatment selection.
Diagnosing Rare Tyrosine Kinase Fusion Diseases
- Diagnose myeloid lymphoid neoplasms with eosinophilia by checking eosinophil count, monocytosis, serum tryptase, vitamin B12, and bone marrow biopsy.
- Look for extramedullary lymphomas or myelosarcomas, as they serve as important diagnostic clues.